Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

NCT04365400 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

233

Enrollment

INDUSTRY

Sponsor class

Stopped Trial prematurely terminated on 03 May 2022 due to the results from an interim analysis indicating a lack of efficacy in the study population.

Conditions

Hypertriglyceridemia
Type 2 Diabetes

Interventions

DRUG: DS102
DRUG: Placebo

Sponsor

Afimmune